Literature DB >> 35687214

Role of Radiation in the treatment of Cushing Disease.

Laurence Katznelson1.   

Abstract

In Cushing disease (CD), radiation therapy (RT) is mostly used in the adjuvant setting in patients who have failed transsphenoidal surgery or have recurrent CD. Stereotactic radiotherapy (SRT) is administered as either single or several sessions, and the most commonly used modalities include photon source (Gamma Knife, CyberKnife, and LINAC) or heavy particles (protons). In multicenter studies, Gamma Knife SRT can lead to biochemical control in 80%, with medial time to remission approximately 15 mos, and 70% recurrence free at 10 years. Conventional RT (CRT) consists of administration of small daily fractions over six weeks, with cumulative dose of 45-50 Gy. Biochemical control is achieved in up to 64% of patients with CRT. Choice of radiation modality includes convenience for patients (SRT is more convenient) and proximity to critical structures. Both forms of RT can result in hypopituitarism. RT remains an important modality for the treatment of patients with CD.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Year:  2022        PMID: 35687214     DOI: 10.1007/s11102-022-01234-y

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   3.599


  2 in total

1.  Long term follow-up of Cushing's disease treated with reserpine and pituitary irradiation.

Authors:  M Murayama; K Yasuda; Y Minamori; L B Mercado-Asis; N Yamakita; K Miura
Journal:  J Clin Endocrinol Metab       Date:  1992-09       Impact factor: 5.958

2.  Management of recurrent and refractory Cushing's disease with reoperation and/or proton beam radiosurgery.

Authors:  Manish K Aghi; Josh Petit; Paul Chapman; Jay Loeffler; Anne Klibanski; Beverly M K Biller; Brooke Swearingen
Journal:  Clin Neurosurg       Date:  2008
  2 in total
  1 in total

1.  Special issue: Cushing's disease update.

Authors:  Maria Fleseriu
Journal:  Pituitary       Date:  2022-08-24       Impact factor: 3.599

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.